20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In a report published Tuesday, Goldman Sachs analyst Robert P. Jones downgraded the rating on Charles River Laboratories (NYSE: CRL) from Neutral to Sell, and lowered the price target from $44.00 to $38.00.
In the report, Goldman Sachs noted, “We downgrade CRL to Sell as we see risk to guidance for RMS (Research Models) constant currency growth of 4%-6% and see little upside to PCS (Preclinical Services). We see 12% downside to our new $38, 12-month price target vs. 4% downside for our CRO coverage. On PCS, recent results and channel checks indicate still subdued early-stage spend and excess capacity as pharma prioritizes late-stage pipelines. For RMS, we estimate (excluding recent acquisitions) sales declined by 2.5% on a constant currency basis, suggesting flat volume growth. All in, we await a broader rebound in Preclinical demand and downgrade CRL as we see little valuation support.”
Charles River Laboratories closed on Monday at $43.21.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!